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Joint torques and powers are reduced during
ambulation for both limbs in patients with
unilateral claudication
Panagiotis Koutakis, MS,a Iraklis I. Pipinos, MD,b Sara A. Myers, MS,a Nicholas Stergiou, PhD,a
Thomas G. Lynch, MD,b and Jason M. Johanning, MD,b Omaha, Neb
Objectives: Symptomatic peripheral arterial disease (PAD) results in significant gait impairment. In an attempt to fully
delineate and quantify these gait alterations, we analyzed joint kinematics, torques (rotational forces), and powers
(rotational forces times angular velocity) in patients with PAD with unilateral claudication for both the affected and
nonaffected legs.
Methods: Twelve patients with unilateral PAD (age, 61.69 ⴞ 10.53 years, ankle-brachial index [ABI]: affected limb 0.59 ⴞ
0.25; nonaffected limb 0.93 ⴞ 0.12) and 10 healthy controls (age, 67.23 ⴞ 12.67 years, ABI >1.0 all subjects) walked over
a force platform to acquire gait kinetics, while joint kinematics were recorded simultaneously. Data were collected for the
affected and nonaffected limbs during pain free (PAD-PF) and pain induced (PAD-P) trials. Kinetics and kinematics were
combined to quantify torque and powers during the stance period from the hip, knee, and ankle joints.
Results: The affected limb demonstrated significantly (P <.05) reduced ankle plantar flexion torque compared to controls
during late stance in both PAD-PF and PAD-P trials. There were significant reductions in ankle plantar flexion power
generation during late stance for both the affected (P <.05) and nonaffected limbs (P <.05) compared to control during
PAD-PF and PAD-P trials. No significant differences were noted in torque comparing the nonaffected limbs in PAD-PF
and PAD-P conditions to control for knee and hip joints throughout the stance phase. Significant reductions were found
in knee power absorption in early stance and knee power generation during mid stance for both limbs of the patients with
PAD as compared to control (P <.05).
Conclusion: Patients with PAD with unilateral claudication demonstrate significant gait impairments in both limbs that
are present even before they experience any claudication symptoms. Overall, our data demonstrate significantly reduced
ankle plantar flexion torque and power during late stance with reduced knee power during early and mid stance for the
affected limb. Further studies are needed to determine if these findings are dependent on the location and the severity of
lower extremity ischemia and whether the changes in the nonaffected limb are the result of underlying PAD or
compensatory changes from the affected limb dysfunction. ( J Vasc Surg 2010;51:80-8.)

Peripheral arterial disease (PAD) affects over 10 million
people in the United States, the majority of which are
elderly. Intermittent claudication is the most common
presentation of PAD and consists of pain, cramping, aching, and tiredness induced by physical activity (ie, walking)
and relieved with rest.1 Intermittent claudication and its
related ambulatory dysfunction are associated with poor
health outcomes, physical dependence, and inactivity2,3
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severely limiting all aspects of patient functioning and
quality of life.4,5
Currently, the ambulatory impairment produced by
claudication and the degree to which it may respond to
treatment are evaluated using basic time-distance tools
such as gait velocity and cadence.6 The majority of available
studies indicate patients with PAD walk slower, have reduced cadence, increased stance time, shorter stride length,
and a narrower step width as compared with controls.6-9
Although these basic temporal and spatial parameters provide
a description of the ambulatory dysfunction of the patient
with PAD, they are unable to provide an understanding of the
mechanisms responsible for this gait impairment.
A series of studies by our laboratory and others have
utilized advanced biomechanical measures to identify the
mechanisms underlying the gait impairment of patients
with PAD. Scott-Pandorf et al26 demonstrated several
mechanisms leading to PAD gait dysfunction. Patients with
PAD walk with decreased fluctuations of center of gravity,
have significantly decreased peak propulsion force, and
exhibit a reduced ability to swing their legs forward.
Crowther et al7 observed abnormal ankle plantar flexion in
early stance, knee range of motion in stance phase, and hip
extension in late stance10 while Chen et al20 demonstrated
significant torque alterations at the ankle and hip.
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To more clearly delineate the joint muscular responses and their contributions in patients with claudication, we have employed advanced biomechanical analysis in the form of joint torques and powers. The joint
torque is the net result of all forces acting around a joint.
Positive torque values represent an extensor response,
while negative values indicate a flexor response. Joint
powers are the product of net torque across a joint and
the angular velocity of the joint. Positive joint power indicates that energy is being generated and is associated with
concentric muscular contraction, while negative power indicates that energy is being absorbed and is associated with
eccentric muscular contraction. The utility of joint powers
is their unique ability to point to specific neuromuscular
deficits in pathologic gait and guide subsequent treatment.
Joint powers have identified the alterations in knee osteoarthritis, anterior cruciate ligament reconstruction,11,12 belowknee amputees,13 and patients with hip arthroplasty,14 while
providing unique rehabilitation protocols in patients undergoing anterior cruciate ligament reconstruction.15 In addition, joint powers have characterized the gait mechanics of the
elderly16-19 and identified the risk for falls in healthy elderly
populations. Similar insights can be gained from advanced
biomechanical analysis of patients with PAD.
Using this approach in our previous work, we have
identified weakness in the posterior compartment muscles
of the calf as a consistent and key factor underlying the PAD
gait adaptations.20 Our previous studies investigated patients with bilateral claudication. Clinically, however, many
patients present with unilateral symptoms having both an
affected limb (AL) and a nonaffected limb (NAL). Therefore, the purpose of our study was to utilize advanced
biomechanical analysis to determine the gait impairment of
the individual limbs of unilateral patients with PAD. Based
on our previous work, we hypothesized that the AL of
patients with PAD would demonstrate significant differences compared to the nonaffected and the control (CON)
limbs while the patients walked before the onset of claudication, these differences would variably worsen after the
onset of claudication symptoms. We also hypothesized that
the NALs would demonstrate no differences as compared
to CON.
METHODS
Subject inclusion and exclusion criteria. Twelve
male patients (age, 61.69 ⫾ 10.53 years, ankle brachial
index [ABI]: AL 0.59 ⫾ 0.25; NAL 0.93 ⫾ 0.12) diagnosed with moderate arterial occlusive disease and unilateral claudication were recruited from the vascular surgery
clinics of the VA Nebraska and Western Iowa and University of Nebraska Medical Centers. In addition, 10 age-,
gender-, body mass-, and height-matched healthy CONs
(age, 66.27 ⫾ 9.22 years; ABI, 1.1 ⫾ 0.11) were recruited
from the community and volunteered to participate. Patients and CONs were screened and evaluated by two
board-certified vascular surgeons. PAD and CON patients
with ambulation-limiting cardiac, pulmonary, neuromuscular, musculoskeletal disease, or those who experienced
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pain or discomfort during walking for any reason other
than claudication were excluded. Patient evaluation included resting ABI (a measurement below 0.9 was present
in the AL of all subjects with unilateral claudication that was
measured in our VA and University of Nebraska Medical
Center Vascular Laboratories), a detailed history, physical
examination, and a direct assessment/observation of the
patient’s walking impairment. All PAD subjects recruited
had no previous attempts at revascularization.
CON subjects had an ABI greater than 1.0 and no
subjective or objective ambulatory dysfunction. CONs
were screened in a similar fashion as patients with PAD and
were excluded for the same ambulation-limiting comorbidities. Informed consent was obtained from all subjects
prior to data collection according to the guidelines of the
Institutional Review Boards of the medical centers. The
gait of all recruited participants was tested in our Biomechanics Laboratory.
Experimental procedure and data collection. Kinematic and kinetic parameters from the ankle, knee, and hip
joints were evaluated in patients with PAD from both the
ALs and NALs before (pain free [PAD-PF]) and after onset
of claudication symptoms (pain [PAD-P]). The limbs were
evaluated during early stance (weight acceptance phase),
mid stance (weight transfer phase), and late stance (weight
propulsion phase). To assess the ambulatory deficits of the
ALs and NALs, patients with PAD were compared to
height-, gender-, mass-, and age-matched healthy CONs.
Prior to data collection, reflective markers were placed at
specific anatomic locations of each subject’s lower limb
utilizing the modified Helen Hayes marker set.21,22 Each
subject walked with his or her self-selected pace on a 10-m
pathway while the three-dimensional marker trajectories and
ground reaction force data were collected simultaneously. The
three-dimensional marker trajectories were collected with an
eight high-speed real-time camera system (EvaRT 5.0, Motion Analysis Corp, Santa Rosa, Calif) surrounding the walkway sampling at 60 Hz. The ground reaction force data were
acquired with a Kistler force platform (Kistler Instrument,
Winterthur, Switzerland) located in the middle of the walkway
sampling at 600 Hz.
Each patient with PAD was tested first in the PAD-PF
condition (before the onset of claudication symptoms),
followed by the PAD-P (after the onset of claudication
symptoms). For the PAD-PF condition, a mandatory rest
period of at least 1 minute occurred between walking trials
to ensure that any pain symptoms had subsided. Once
patients completed all PAD-PF trials, claudication was induced. To accomplish this, a clinical protocol was used that
consisted of walking on a treadmill set at 10% grade and at
a speed of 0.67 m/second23,24 until the onset of pain. At
this time, patients were immediately removed from the
treadmill and returned to the collection walkway to acquire
the data for the pain condition without the mandatory
resting periods between trials. The CON subjects completed five walking trials with mandatory rest of 1 minute
between the trials. A total of five successful trials were
collected from each limb of the subjects for each condition.
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Fig 1. An illustration of the stance phase of walking with the dominant flexor and extensor muscle groups that are
involved in the three phases is produced. The dominant muscle groups are identified in red if they contract
concentrically and in purple if they contract eccentrically. a, Early stance phase lasts from ipsilateral heel strike to
contralateral toe off thus covering the first double support phase (initial 20% of stance). The right leg is accepting the
majority of body weight as it descends from previously being in single support on the left leg. In this phase, the right
hip extensors concentrically contract to extend the hip, the knee extensors eccentrically contract to allow the knee to
bend, and the ankle dorsiflexors eccentrically contract to maintain ankle dorsiflexion. b, Mid stance phase lasts from
contralateral (here left) toe off until contralateral heel strike. During single support, the body is at its highest point over
the extended ipsilateral leg. The body has maximum potential energy preparing to fall forward for the next double
support. Limited muscular contractions are needed during this phase except when the knee extensors contract
concentrically to extend the knee and straighten the leg. c, Late stance lasts from contralateral heel strike to ipsilateral
toe off. It is the final 20% of stance and is the second double support phase. In this phase, the body is propelled forward
onto the extended left leg mainly by the action of the ankle plantar flexors. Functionally, these muscles contract
concentrically and accelerate the leg and the trunk forward and upward over the left leg thus providing forward
progression and weight support.

A successful walking trial was determined by the subject’s
foot being completely within the force platform.
Data analysis. Data from the three-dimensional marker trajectories and ground reaction forces were combined to calculate the joint torques and powers for the
sagittal plane during the stance phase of walking (from heel
touchdown to toe off). The limbs were evaluated during
early stance (weight acceptance phase), mid stance (weight
transfer phase), and late stance (weight propulsion phase)
(Fig 1). A low-pass fourth-order Butterworth filter with a 7
Hz cutoff frequency was used to smooth the marker trajectories during postdata processing. An inverse dynamic technique was performed to calculate joint torques and joint
muscle powers from the kinematic (displacement velocities
and accelerations derived from the three-dimensional
marker trajectories) and the kinetic (derived from the
ground reaction forces) data.25 Joint torque was calculated
as the summation of all torques acting around a specific
joint. These torques are the product of all muscular, ligament, frictional, gravitational, inertial, and ground reaction
forces acting on the joint. Positive torque values represent
extensor torques while negative values indicate flexor torques. Joint muscle power was calculated as the product of
the net torque at a joint (Tj) and joint angular velocity (j)
or Pj⫽Tj x j. Power measurements can be expressed positively or negatively. Positive power indicates energy is being
generated (concentric muscular contractions) and negative

power indicates energy is being absorbed (eccentric muscular contractions) by the joint muscle group under study.
Joint torques and joint muscle powers were normalized by
body weight and expressed as a percentage (100%) during
stance phase from heel strike (0% stance) to toe-off (100%
stance). Peak torques were measured for the following
muscle groups: ankle dorsiflexors, ankle plantar flexors,
knee extensors, knee flexors, hip extensors, and hip flexors.
The peak variables indentified for joint powers were: ankle
power absorption in mid stance (A1), ankle power generation in late stance (A2), knee power absorption in early
stance (K1), knee power generation in early stance (K2),
knee power absorption in late stance (K3), hip power
generation in early stance (H1), hip power absorption in
mid stance (H2), and hip power generation in late stance
(H3). All normalization occurred after the peak points were
determined to ensure that the normalization did not distort
these values. Joint torques and joint powers were calculated
and normalized using custom software in Matlab (Matlab
2007, Mathworks Inc, Concord, Mass).
Statistical analysis. Group means for all dependent
variables were calculated for each testing condition
(PAD-PF and PAD-P) for all limbs. Thus, 12 ALs and 12
NALs were evaluated for the patients with PAD in each
condition compared to 20 limbs for the CON group. A
two-by-two fully repeated measures analysis of variance was
used to compare the two limbs for both PAD-PF and
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Table I. Baseline characteristics of patients with
peripheral arterial disease (PAD) and healthy controls
Clinical
characteristics

Control
(n ⫽ 20 limbs)

PAD
(n ⫽ 24 limbs)

P value

Age (years)
Body mass (kg)
Body height (m)
Disease duration
(years)
ABI
Nonaffected limb
Affected limb
Right for control
Left for control
Smokers, n (%)
Hypertension, n (%)
Diabetes mellitus,
n (%)
Dyslipidemia, n (%)
BMI

66.27 ⫾ 9.22
77.89 ⫾ 10.65
1.74 ⫾ 0.08

61.69 ⫾ 10.53
84.65 ⫾ 20.24
1.72 ⫾ 0.08

ns
ns
ns

0

6.25 ⫾ 3.84

N/A

.93 ⫾ .12
.59 ⫾ .25

ns

1.1 ⫾ .12
1.1 ⫾ .08
8 (80)
0 (0)
0 (0)
0 (0)
25.60 ⫾ 2.94

7 (58.3)
5 (41.7)
1 (8.3)
9 (75)
27.42 ⫾ 4.44

⬍.05
ns
⬍.05
ns
⬍.05
ns

ABI, Ankle brachial index; BMI, body mass index; ns, statistically nonsignificant; N/A, not applicable.
Values are presented as means ⫾ standard deviations.

PAD-P conditions. Independent t tests were used to compare both conditions and both limbs of the PAD group
with the CON group. Independent t tests were also used to
compare the differences between PAD and CON group
demographics. The level of significance was set to 0.05.
Values are presented in the tables and figures as means ⫾
standard deviations. The SPSS Base 12.0 statistical software
(SPSS Inc, Chicago, Ill) was used to perform the statistical
analysis.
RESULTS
Subjects. Twelve patients with PAD with clinically
diagnosed aortoiliac (n ⫽ 4), femoropopliteal (n ⫽ 4), and
multilevel (n ⫽ 4) occlusive disease and calf claudication
were evaluated. All patients had Rutherford category 2
moderate claudication symptoms. Ten CON subjects with
absence of claudication were also included (Table I).
Joint torques and powers
Early stance. Significant reduction in ankle dorsiflexion torque was noted for the AL during early stance in the
PAD-P condition as compared to CONs. The knee extensor torque was reduced during early stance for the AL in
both PAD-PF and PAD-P conditions as compared to
CONs (Table II; Fig 2). Knee power absorption during
early stance was significantly reduced for the AL in both
PAD-PF and PAD-P conditions as compared to CONs
(Table III; Fig 3) whereas reduction for the NAL was noted
in the PAD-PF condition (Table III; Fig 4). The knee
power generation during early stance was significantly reduced for both limbs in the PAD-PF and PAD-P conditions
as compared to CONs. In addition, the knee power generation during early stance was significantly reduced in the
PAD-PF condition as compared to PAD-P primarily in the
NAL (Table III).

Midstance. Hip power absorption in mid stance was
significantly reduced in the NAL in both PAD-PF and
PAD-P conditions as compared to CONs (Table III).
Late stance. Significant reduction in ankle plantar
flexion torque was noted for the AL in both PAD-PF and
PAD-P conditions during late stance as compared to CONs
(Table III; Fig 2). Ankle power generation during late
stance was significantly reduced for the limbs as compared
to CONs for both the PAD-PF and PAD-P conditions
(Table III; Figs 3 and 4). In addition, significant reductions
in ankle power generation were noted during the PAD-P
condition compared to the PAD-PF condition for both
limbs of the patients with PAD (Table III).
DISCUSSION
The present study is the first to provide detailed quantitative analysis of the joint torque and joint power changes
in patients with PAD with unilateral intermittent claudication. While prior works have examined the biomechanics of
symptomatic PAD limbs,7,26 the current study is unique in
simultaneously evaluating symptomatic and asymptomatic
limbs of patients with PAD with classic symptom unilateral
claudication. Joint torques and joint powers were evaluated while patients with PAD walked both before and after
the onset of claudication (PAD-PF and PAD-P conditions, respectively) and were compared to those of gender-,
height-, mass-, and age-matched healthy CONs. Our data
demonstrate that the gait of claudicating patients is significantly altered for both limbs in both the PAD-PF and
PAD-P conditions.
Our results continue to identify a weakness in the
posterior compartment muscles of the calf as the primary
dysfunction operating in the patient with PAD producing
significantly altered ankle propulsion during late stance.20
Compared to CONs, patients with PAD have decreased
power generation in both their limbs as they try to propel
toward swing in late stance in both PAD-PF and PAD-P
conditions (Table III; Figs 2 and 3). The decreased power
generation during plantar flexion points to a significant
weakness of the posterior calf muscles (primarily the gastrocnemius and soleus), which constitutes the dominant
muscle group responsible for ankle plantar flexion (push-off
initiating the swing phase). Weakness of the posterior calf
muscles is consistent with this muscle group being the
“functional end organ” in lower extremity ischemia. This
hypothesis is further supported by findings demonstrating
that patients with PAD have significantly decreased ankle
plantar flexor strength3,27-29 and decreased ankle plantar
flexor torque. Importantly, advanced biomechanical analysis demonstrated the specific dysfunction with a limited
number of patients (n ⫽ 22) compared to other methodologies (n ⫽ 500-1500). Functionally, in late stance the
gastrocnemius and the soleus both concentrically contract
to propel the body forward and initiate leg swing while
decelerating the downward motion of the trunk (ie, providing forward progression and support).30 Our advanced
biomechanical analyses clearly identifies the most definable
and obvious deficit in patients with PAD, regardless of the
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Table II. Group means and standard deviations for joint torques of the ankle, knee, and hip joint for peripheral arterial
disease (PAD) and control groupsa,c
PAD (n ⫽ 24 limbs)

ADT
APT
KET
KFT
HET
HFT

Pain Free (PAD-PF)

Pain (PAD-P)

Control
(n ⫽ 20 limbs)

Nonaffected limb

Affected limb

Nonaffected limb

Affected limb

⫺0.36 ⫾ 0.09
1.31 ⫾ 0.28
0.82 ⫾ 0.18
⫺0.14 ⫾ 0.12
0.98 ⫾ 0.49
⫺0.95 ⫾ 0.21

⫺0.38 ⫾ 0.20
1.32 ⫾ 0.16
0.61 ⫾ 0.30
⫺0.23 ⫾ 0.21
0.83 ⫾ 0.33
⫺0.72 ⫾ 0.39

⫺0.29 ⫾ 0.13
1.18 ⫾ 0.25a,c
0.58 ⫾ 0.27a
⫺0.14 ⫾ 0.22
0.72 ⫾ 0.15
⫺0.96 ⫾ 0.51

⫺0.42 ⫾ 0.30
1.27 ⫾ 0.18
0.69 ⫾ 0.41
⫺0.20 ⫾ 0.28
0.80 ⫾ 0.23
⫺0.76 ⫾ 0.43

⫺0.23 ⫾ 0.15b
1.11 ⫾ 0.27b
0.59 ⫾ 0.37b
⫺0.13 ⫾ 0.26
0.78 ⫾ 0.24
⫺0.90 ⫾ 0.65

ADT, Ankle dorsiflexion torque; APT, ankle plantar flexion torque; KET, extensor torque; KFT, flexor torque; HET, hip extensor torque; HFT, hip flexor
torque.
The units for all values are N*m/kg.
a
P ⬍.05, Significant differences between groups (PAD-PF, affected limb vs control).
b
P ⬍.05, Significant differences between groups (PAD-P, affected limb vs control).
c
P ⬍.05, Significant differences between testing conditions (PAD-PF vs PAD-P).

Fig 2. The ensemble-average joint torque curves of the affected limb for the patients with peripheral arterial
disease-pain free (PAD-PF) and peripheral arterial disease-with pain (PAD-P; n ⫽ 24 limbs) and the healthy controls
(control, n ⫽ 20 limbs) during the stance phase for the (a) ankle and (b) knee joints. Torques are normalized to body
mass in kg. Error bars represent the standard deviation of the mean values. ADT, Ankle dorsiflexion torque; APT, ankle
plantar flexion torque; KET, extensor torque; KFT, flexor torque.
b
P ⬍.05, Significant differences between groups (PAD-PF affected limb vs control).
d
P ⬍.05, Significant differences between groups (PAD-P affected limb vs control).
e
P ⬍.05, Significant differences between testing conditions (PAD-PF vs PAD-P).

degree of limb ischemia, as a failure of the ankle plantar
flexors to optimally contract producing decreased power
output in late stance.
There were notable findings at the knee and hip for the
current study when examining torque and power data.

Knee extensor torque (Fig 2) in early stance was decreased
in both PAD-PF and PAD-P conditions for the AL as
compared to CONs. The knee power absorption in early
stance and knee power generation in mid stance (both
serving to decelerate trunk descent on the supporting limb)
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Table III. Group means and standard deviations for joint powers of the ankle, knee, and hip joint for peripheral arterial
disease (PAD) and control groups
PAD (n ⫽ 24 limbs)

A1
A2
K1
K2
K3
H1
H2
H3

Pain free (PAD-PF)

Control
(n ⫽ 20 limbs)

Nonaffected limb

⫺0.52 ⫾ 0.21
4.00 ⫾ 0.88
⫺0.73 ⫾ 0.22
0.62 ⫾ 0.25
⫺0.73 ⫾ 0.23
0.42 ⫾ 0.20
⫺0.78 ⫾ 0.23
0.76 ⫾ 0.29

⫺0.37 ⫾ 0.35
2.65 ⫾ 0.92a,e
⫺0.52 ⫾ 0.40a
0.31 ⫾ 0.23a,e
⫺0.67 ⫾ 0.57
0.39 ⫾ 0.21
⫺0.65 ⫾ 0.36a
0.77 ⫾ 0.37

Affected limb
⫺0.43 ⫾ 0.18
2.49 ⫾ 0.46b,e
⫺0.36 ⫾ 0.21b
0.25 ⫾ 0.25b,e
⫺1.09 ⫾ 1.05
0.38 ⫾ 0.20
⫺0.68 ⫾ 0.35
0.78 ⫾ 0.51

Pain (PAD-P)
Nonaffected limb

Affected limb

⫺0.53 ⫾ 0.16
2.39 ⫾ 0.67c
⫺0.75 ⫾ 0.74
0.41 ⫾ 0.28c
⫺0.66 ⫾ 0.53
0.41 ⫾ 0.20
⫺0.58 ⫾ 0.54c
0.57 ⫾ 0.42

⫺0.43 ⫾ 0.15
2.05 ⫾ 0.59d
⫺0.36 ⫾ 0.32d
0.26 ⫾ 0.31d
⫺1.00 ⫾ 1.20
0.31 ⫾ 0.29
⫺0.68 ⫾ 0.45
0.62 ⫾ 0.55

A1, Ankle power absorption in late mid stance; A2, ankle power generation in late stance; K1, knee power absorption in early stance; K2, knee power generation
in early mid stance; K3, knee power absorption in late stance; H1, hip power generation in early stance; H2, hip power absorption in mid stance; H3, hip power
generation in late stance.
The units for all values are watts/kg.
a
P ⬍.05, Significant differences between groups (PAD-PF, nonaffected limb vs control).
b
P ⬍.05, Significant differences between groups (PAD-PF, affected limb vs control).
c
P ⬍.05, Significant differences between groups (PAD-P, nonaffected limb vs control).
d
P ⬍.05, Significant differences between groups (PAD-P, affected limb vs control).
e
P ⬍.05, Significant differences between testing conditions (PAD-PF vs PAD-P).

Fig 3. The ensemble-average joint power curves of the affected limb for the patients with peripheral arterial disease-pain
free (PAD-PF) and peripheral arterial disease-with pain (PAD-P; n ⫽ 24 limbs) and the healthy controls (control, n ⫽ 20
limbs) during the stance phase for the (a) ankle and (b) knee joints. Note: A1 ankle power absorption in late mid stance, A2
ankle power generation in late stance, K1 knee power absorption in early stance, K2 knee power generation in early stance,
K3 knee power absorption in late stance. Error bars represent the standard deviation of the mean values.
b
P ⬍.05, Significant differences between groups (PAD-PF affected limb vs control).
d
P ⬍.05, Significant differences between groups (PAD-P affected limb vs control).
e
P ⬍.05, Significant differences between testing conditions (PAD-PF vs PAD-P).

for both limbs of the patients with PAD were significantly
reduced as compared to CONs. In addition, hip power
absorption (stabilizing the trunk on the moving lower limb
in preparation for push-off) was significantly reduced dur-

ing mid stance for the NAL during PAD-PF and PAD-P
trials as compared to CONs. Our current data in patients
with unilateral claudication along with our recently published work in patients with bilateral claudication,20,31 sug-

86 Koutakis et al

JOURNAL OF VASCULAR SURGERY
January 2010

Fig 4. The ensemble-average joint power curves of the non-affected limb for the patients with peripheral arterial
disease-pain free (PAD-PF) and peripheral arterial disease-with pain (PAD-P; n ⫽ 24 limbs) and the healthy controls
(control, n ⫽ 20 limbs) during the stance phase for the (a) ankle and (b) knee, joints. A1, Ankle power absorption in
late mid stance; A2, ankle power generation in late stance; K1, knee power absorption in early stance; K2, knee power
generation in early mid stance; K3, knee power absorption in late stance. Error bars represent the standard deviation of
the mean values.
a
P ⬍.05, Significant differences between groups (PAD-PF, nonaffected limb vs control).
c
P ⬍.05, Significant differences between groups (PAD-P, nonaffected limb vs control).
e
P ⬍.05, Significant differences between testing conditions (PAD-PF vs PAD-P).

gest that alterations at the knee and hip result in abnormal
trunk support during walking in patients with PAD. Combined with the abnormal power generation at the ankle
level in late stance, the claudicating patient may be unable
to accept and support the weight of the trunk, especially
after the onset of claudication pain. Future studies will need
to explore the gait handicap of patients with PAD with
aortoiliac occlusive disease (ie, buttock and thigh claudication) compared to patients with femoral-popliteal occlusive
disease (ie, calf claudication) to determine if these patterns
persist.
The current study examines unilateral claudication patients with a clear focus on the “asymptomatic” limb. Most
vascular specialists in a clinical setting would focus solely on
the symptomatic limb, especially with an asymptomatic
contralateral limb and normal ABI. Additionally, most
clinicians would assume the normal limb would compensate for the dysfunction of the AL. Several important findings should be noted for this asymptomatic limb. First,
despite absence of symptoms, the NAL demonstrates significant reductions in joint powers when compared to the
CON limbs. These differences are demonstrated clearly for
the ankle power generation at late stance, knee power
absorption and generation in early stance, and hip power

absorption at mid stance. Secondly, when comparing the
NAL to the AL directly, no statistically significant differences were found indicating similar joint muscular responses in both legs. Therefore, our data demonstrate
abnormal gait biomechanics for the NAL in the unilateral
claudicant.
The main pathophysiologic mechanism operating in
claudication is exercise-induced ischemia of the muscles in
the symptomatic limbs, which is followed by reperfusion at
rest.32-37 These repeated cycles of ischemia/reperfusion
have been shown to be responsible for the myopathy of
claudicating muscles, which is principally characterized by
mitochondrial dysfunction and oxidative damage. Interestingly, in two studies38,39 evaluating levels of mitochondrial
DNA damage in muscles from ALs and NALs of patients
with unilateral PAD, Bhat et al38 demonstrated that mitochondrial damage was present in both limbs despite a
normal ABI and absence of symptoms in the NAL. Our
findings, coupled with those of Bhat et al,38 suggest that
ischemia/reperfusion of the AL may have an effect (possibly by systemic oxidative stress or another neuro/humoral
pathway) on the NAL. An alternative explanation for our
findings is subclinical occlusive disease in the nonaffected
and asymptomatic limbs not detected at rest but present
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with exertion. Although our patients had normal resting
ABIs and no symptoms in their NAL, we did not evaluate
them using exercise treadmill testing, which could have revealed occlusive disease in the NAL that is not discernible
by ABI measurements at rest. Finally, it is possible that the
NAL may be suffering overuse injury because of an attempt
by the patient with PAD to protect the symptomatic limb,
or in contrast the NAL may be deconditioned because of
the limitations to ambulation posed by the AL. Regardless
of the mechanism, it is clear that the NAL in unilateral PAD
is not simply an innocent bystander.
In summary, biomechanical analysis using joint torques
and powers indicates significant abnormalities in the gait of
NALs and ALs in both PAD-PF and PAD-P conditions for
patients with unilateral claudication. Our research work
points to significant calf muscle dysfunction leading to an
inability to propel the body as the primary gait deficit in
patients with PAD. Additional impairments at the knee and
hip affecting weight transfer are also present. These findings demonstrate that advanced biomechanical analysis correlates with basic laboratory data and can be used to fully
define the underlying gait handicap of patients with PAD.
Advanced biomechanical gait analysis, therefore, holds the
potential to assess, in a limited number of patients, the
effect of exercise walking programs, medication regimens,
and revascularization to determine the degree to which the
gait dysfunction of claudicating patients is ultimately recoverable.
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